Shopping Cart
Remove All
Your shopping cart is currently empty
Avizakimab (BOS161721) is a humanized lgG1 monoclonal antibody that targets and inhibits the biological activity of IL-21, with potential for the treatment of systemic lupus erythematosus (SLE).
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $290 | - | In Stock | |
| 5 mg | $723 | - | In Stock | |
| 10 mg | $986 | - | In Stock | |
| 25 mg | $1,490 | - | In Stock | |
| 50 mg | $1,970 | - | In Stock |
| Description | Avizakimab (BOS161721) is a humanized lgG1 monoclonal antibody that targets and inhibits the biological activity of IL-21, with potential for the treatment of systemic lupus erythematosus (SLE). |
| In vitro | In vitro, Avizakimab blocks IL-22 binding to IL-22R1 and inhibits downstream STAT3 phosphorylation[1]. |
| Synonyms | BOS161721, BOS 161721 |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | < 1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID |
| Cas No. | 2229685-51-0 |
| Color | Transparent |
| Appearance | Liquid |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.